Comparison · NCT02032823-9b419860
Olaparib vs Placebo: Invasive Disease Free Survival (IDFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olaparib vs Placebo: Invasive Disease Free Survival (IDFS). Trial comparisons, record NCT02032823-9b419860. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02032823-9b419860
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.115 | 0.0961 | 0.137 | wilson | |
| Risk in group 2 | 0.195 | 0.17 | 0.221 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0794 | -0.112 | -0.0465 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.592 | 0.474 | 0.739 | log | |
| Odds ratio, group 1 over group 2 | 0.539 | 0.415 | 0.699 | log | |
| Number needed to treat, for one fewer participant with the outcome on Olaparib than on Placebo | 12.6 | 8.9 | 21.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olaparib | Olaparib tablets 300mg taken orally twice daily. | 106 | 921 | OG000 |
| Group 2 | Placebo | Placebo tablets taken orally twice daily. | 178 | 915 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Invasive Disease Free Survival (IDFS)
- Description
- An IDFS event is defined as the first occurrence of loco-regional or distant recurrence or new cancer or death from any cause.
- Time frame
- From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months)
- Population
- Full Analysis Set (FAS)
Source ClinicalTrials.gov
Trial
- Title
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
- NCT number
- NCT02032823
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Olaparib, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2021-12-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02032823?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02032823-9b419860